Accredited by the European School of Veterinary Postgraduate Studies (ESVPS) and due to be validated by Harper Adams University, Improve says the new Cert will be delivered over 14 modules in three blocks of training by globally recognised experts in practical training centres in Sheffield, UK; Cremona, Italy and Madrid, Spain.
The modules will be supported by an online learning platform providing notes, additional learning resources and the ability for delegates to discuss clinical cases in a closed forum.
David Babington MRCVS, Business Development Director at Improve International, said: "Our GPAdvCert in Small Animal Soft Tissue Surgery is a natural progression for veterinary surgeons who want to develop their soft tissue surgery skills.
"The programme focuses on problem-solving to increase confidence in diagnosing and stabilising animals with complex pathologies and delegates will have plenty of opportunity to practise new surgical techniques and advanced procedures under close supervision in a wet-lab environment."
He added: "In common with our other GPAdvCerts in Orthopaedics and Small Animal Medicine, achieving this qualification will help vets in practice to reduce the number of patients they have to refer, enabling them to retain a higher level of income for their practice. The programme will also provide them with skills which they can pass onto their team."
The GPAdvCert in Small Animal Soft Tissue Surgery is aimed at veterinary surgeons who have already completed a General Practitioner Certificate in Small Animal Surgery (GPCertSAS) or a Postgraduate Certificate (PgC) in Small Animal Surgery.
Improve says the successful achievement of a GPAdvCert enables delegates to progress from a Postgraduate Certificate (or equivalent) to the Postgraduate Diploma in Advanced Veterinary Practice Sciences in the UK, which is awarded by Harper Adams University. This can, in turn, be used towards the award of a Master’s Degree (MSc) in Advanced Veterinary Practice Sciences.
According to the AHT, glaucoma affects more than a thousand dogs across the UK. Now Border Collie breeders will be able to use this test to reduce the risk of producing glaucoma-affected puppies, whilst maintaining genetic diversity.
The work that resulted in the new test began at the Roslin Institute in Edinburgh, where scientists found a variant in a gene called OLFML3 reported to be associated with severe goniodysgenesis and glaucoma in Border Collies.
On reading this research, the AHT’s canine genetics team, which has an ongoing research programme looking at canine glaucoma, began to look at how a DNA test could be offered based on the mutation.
Hattie Wright, Vets4Pets Research Assistant at the AHT, genotyped a large cohort of Border Collies for the mutation, in order to obtain an accurate measure of the association between the mutation and goniodysgenesis and glaucoma in the Border Collie. These dogs all had their eyes examined, and their DNA collected, by veterinary ophthalmologist James Oliver.
The charity’s findings from this validation process replicated the findings of the Roslin Institute, so the AHT has been able to develop and launch a DNA test based on the reported OLFML3 mutation.
Dr Cathryn Mellersh, Head of Canine Genetics at the Animal Health Trust, said: "We’re delighted to offer this test to Border Collie breeders and hope in time, through its use, we can lessen the prevalence of this disease in this lovely breed.
"Our research has found that the mutation is only associated with glaucoma in Border Collies, so we will publish our data at the earliest opportunity, in the hope that other commercial DNA testing providers will not be tempted to make the DNA test available to breeds other than the Border Collie."
For more information, visit: www.ahtdnatesting.co.uk
The new vaccine offers up to 12 months' immunity against three of the biggest diseases that cause reproductive failures in pigs.
Alexandre Carvalho, business unit manager for pigs at MSD Animal Health, says the vaccine has the broadest protection against Leptospira on the market, offering protection against nine different serogroups including, Australis and Pomona.
He added: "This vaccine also includes protection against the Tarassov serogroup, which is unique to the product.
"It’s important to note that PORCILIS Ery+Parvo+Lepto can be used for mass vaccination and during pregnancy, which hasn’t been possible with previous products."
Pet Anxiety Month aims to educate pet owners about the signs of anxiety in cats and dogs, help them identify the causes, and encourage them to take steps to support anxious pets (presumably by putting multiple diffusers in every home and blanketing large swathes of suburbia in a pea soup fog of pheromones).
Joking aside, the initiative comes on the back of the PDSA Animal Wellbeing report1 which revealed that over half of veterinary professionals think they've seen an increase in dog behavioural issues in the last two years, with over three-quarters of dog owners saying that they would like to change at least one behaviour displayed by their dog and nearly 90% of owners reporting that their cat is afraid of at least one thing.
To support the initiative, Ceva will be running a TV advertising campaign from 7 March until 21 April, which directly targets dog lovers during More4’s Crufts’ programmes (from 7 to 10 March).
The advertisements will also air on Channel 4, Channel 4 partner channels, Sky and Sky partner channels. Both advertisements are 30 seconds long.
Ceva is producing a marketing pack to raise awareness of Pet Anxiety Month containing eye-catching display materials and a social media toolkit.
Abigail King, Ceva's senior behaviour product manager, said: "More and more people are identifying anxiety and behavioural issues in their pets. Pet Anxiety Month will highlight signs of anxiety in cats and dogs that perhaps an owner is unaware of, help identify the problem and encourage changes both in and out of the home to make the household a happier place."
For further information, visit www.petanxiety.co.uk or Pet Anxiety Month on Instagram or Facebook.
40% of the dry food is a 'flour' made from Hermetia illucens larvae reared in a new, £18 million facility in Holland. Other ingredients include British grown oats, potato and a number of other botanicals.
Insects require only a small fraction of the resources to farm than other forms of protein, such as chicken or beef. The manufacturer says that compared to beef, its grubs need just 2% of the land and 4% of the water to produce each kilogram of protein, which means they generate 96% less greenhouse emissions. And they don't need any antibiotics or growth hormones.
The manufacturer also says insects are easier to digest than chicken, making Yora ideal for pets with sensitive stomachs.
TV vet Rory Cowlam MRCVS is throwing his weight behind the new dog food. He said: "Yora provides a healthy, high protein alternative to conventional kibble. It’s hypoallergenic, and free from antibiotics and growth hormones. Pets love the taste – plus it’s great for the planet.
"As a keen conservationist and dog lover, I am incredibly excited by the enormous potential for this dog food to reduce our pets’ collective carbon pawprint."
Tom Neish, founder of Yora, said: "Animals and humans have been eating insects since the dawn of time and we believe Yora is the future of pet food. We have trialled 29 recipes to find the perfect combination of great tasting ingredients and are very proud of the end result.
"Yora enables dog owners to take the lead in giving their dog a nutritious, tasty food whilst having a positive impact on the environment."
Yora is available to buy online or from Pets Corner stores, priced at £13.99 for a 1.5kg bag.
If you're interested in stocking Yora at your practice, contact Hollie Smith, Marketing and Operations Manager on 01293 265618, or email hollie@yorapetfoods.com
Now, I'm off to buy a bag for my dog. I figure it should be easier to persuade Daisy that an insect-based diet is necessary to save the planet, than my wife.
If you are speaking at or hosting a small animal CPD event in 2019, please email details to press@vetsurgeon.org for it to be considered for addition to this list.
This list includes events from CPD Solutions, Improve International, the Veterinary Poisons Information Service and the Small Animal Medicine Society.
Veterinary nurses, veterinary surgeons, students and other veterinary professionals are all invited to take part in the anonymous survey and share incidents where they have witnessed discrimination or felt discriminated against.
The survey covers the nine protected characteristics under the Equality Act: age, gender reassignment, marital or partnership status, being pregnant, disability, race, religion, sex and sexual orientation. It also includes other forms of discrimination which might not fit under these characteristics, such as body weight and socio-economic background.
BVA Junior Vice President Daniella Dos Santos said: "The veterinary professions should be open, welcoming and supportive of everyone; however, it is clear from the reports we’re hearing that discrimination is still an issue. Worse still, we’re aware that some colleagues have faced a backlash when talking about their experiences of discrimination. This is completely unacceptable.
"If we hope to prompt meaningful change we need to fully understand the scale of the problems our colleagues are facing. To do that it’s important that we provide a safe, anonymous space for everyone to share their experiences. We hope this questionnaire will give people that opportunity and we would like to sincerely thank our colleagues for their willingness to share their personal experiences with us."
The survey was developed with the support of the British Veterinary Ethnicity and Diversity Society (BVEDS) and British Veterinary LGBT+.
BVA says it intends to gather further quantitative data on discrimination via its Spring Voice of the Veterinary Profession Survey 2019.
The questionnaire is open from 2 February until 2 March and should take around 10 minutes to complete. A link to the questionnaire is available here.
The company says that so far, it has had no cases of flu reported in horses vaccinated with Equip F or Equip FT in the UK. However, it cautions that in the present flu outbreak it is not clear if any of the current influenza vaccines will provide complete clinical protection against the mutated strain.
In addition, Zoetis highlights that:
Equip F and Equip FT are both indicated for reduction in clinical signs caused by Equine Influenza, including Florida Clade 1 strains.
Cross protection has been demonstrated by virulent challenge for representative strains of Florida Clade 1 (Paillot et al 20081, Bryant et al 20102) and Clade 2 (Paillot et al 20153).
Vaccination with Equip F stimulated a flu specific cell-mediated immune response to a Clade 1 strain which was detectable for up to one year after the third vaccination in primary course (Paillot et al 20153).
Zoetis says it is confident that the Equip range continues to be effective against its licensed indications.
If you have further questions about the vaccines, ring 0845 300 8034 and choose option 1 to speak to Zoetis' technical team.
References
Henry Schein said in a statement on Friday that it had sold the business in order to focus on its dental and medical markets and pursue new investment opportunities.
Covetrus says it will be using the experience, technology and global scale of the merged companies to provide veterinary practices with a more comprehensive set of integrated services and technology solutions, and tools to strengthen client relationships and grow their practice.
Covetrus launched on Nasdaq last Friday, when President and Chief Executive Officer Benjamin Shaw, said: "Today marks an important new chapter in the world of veterinary medicine, as we launch Covetrus as a new company listed on Nasdaq.
"We look forward to strengthening our customer relationships and expanding our veterinary practice partnerships worldwide as we bring more comprehensive and powerful solutions to market to meet their evolving needs and improve health and financial outcomes."
Jason has a very personal reason for supporting the charity: his wife is one of the 100 people diagnosed with MS each week: "My wife, Adele, was diagnosed with MS a few years ago and the support and information we have received from the MS Trust has been invaluable in helping us as a family to come to terms with the condition."
The MS Trust offers trusted information, a friendly voice to speak to and the funding and training of vital MS nurses. Each month the charity responds to on average 271 enquiries and sends out around 3,700 information booklets.
To support Jason's efforts, visit: uk.virginmoneygiving.com/jasondavidson
Chanelle's head of sales and marketing, Killian Gaffney said: "The total UK market is around 80,000 bottles annually. However, with the major supplier announcing some re-stocking in March but full availability still under question, there is a real sense of urgency for practitioners.
"The Chanelle team worked throughout December with our manufacturing division to ensure that the UK product shortfall could be alleviated.
"Air freighting supplies seemed the obvious course of action, and ensured we could supply the UK market as quickly as possible."
For further information, contact: Chanelle on 00353 91 841 788.
The company says it's not just older horses suffering from joint disease, 36% of horses developed the condition by the time they were eight years old.
In the survey, 69% of horses needed up to five visits to their veterinary surgeon for treatment, while 21% needed as many as ten visits. Horse owners spent an average of £2,104 treating their horse’s joint condition while 5% spent more than £7,500 on the problem.
In addition, 53% said they've missed up to ten competitions due to joint disease, with 17% missing more than 20 competitions.
The survey revealed that joint problems are an ongoing concern for many. 76% of owners said they worry about their horse developing osteoarthritis and 30% had retired a horse earlier than expected owing to joint disease. In addition, 84% admitted that they would not buy a horse if they knew it had joint problems.
In terms of joint care, 74% of respondents said they give their horse a joint supplement. 69% check their horse's legs daily and 90% implement post-competition leg care measures.
Cavalor’s Lieselot Hamerlinck said: "It is good to see that so many horse owners are using a joint supplement but it’s important that they understand what to look for when choosing which product to use. They should look for anti-inflammatory products, not just joint support and for clinical evidence on any product claims. It’s not just about giving a joint supplement every day, it’s more about giving the right product tailored to the horse’s individual needs.
"Also horse owners should be mindful that it is equally important, if not more so, to take proper care of their horse’s joints all year round, not just during competition."
For further information, visit www.cavalor.com.
Reference
In its updated position statement, the association emphasises its support of current UK legislation and says it would like to see improved implementation of current laws, in particular when informed by an evidence-based welfare outcomes approach.
The BVA also recommends that any proposals to improve welfare during transport should embrace all forms of transport and include welfare issues before, during and after movement. This, it says, would help ensure that a well-defined set of animal welfare standards are met for the entirety of any journey.
The BVA recommends that animals are slaughtered as close to the point of production as possible and supports the exploration of further opportunities which would assist this. It recognises that transportation of live animals can be unavoidable in some situations – for example, journeys between the Scottish Islands and Highlands – but says that no animal should be exported to a destination with unknown welfare standards, to one using systems currently banned in the UK or to a country where it would be slaughtered without stunning.
BVA President Simon Doherty said: "Any kind of movement has the potential to impact on an animal’s health and welfare. Ideally, we’d like to see livestock slaughtered close to the point of production, as long as all legislative health and welfare standards can be maintained. However, we recognise the high standards of welfare in the UK and support better implementation of current legislation.
"We have taken care to reiterate that any improvements made to live animal transport should consider welfare issues before, during and after movement so that a more complete approach is taken on this issue.
"We recognise that journey length is not the only influencer of welfare conditions for animals, and transport needs to be looked at as a whole rather than focusing on single factors. The most important thing for Government to do is to consider the evidence base when it weighs up options for making improvements."
Lynne was instrumental in creating the Linnaeus business in January 2015, and then growing it to the point where it now has 145 veterinary practices across the UK.
Lynne will be staying on as a consultant for Mars Petcare, which acquired Linnaeus in June 2018. She said: "As much as I would love to be part of the continuing journey and success of Linnaeus, I feel it is right for me to step back from the total time commitment required to be a CEO."
Paul Coxon, Linnaeus Chief Financial Officer, said: "The Linnaeus Group’s achievements under Lynne’s leadership cannot be underestimated. Since 2015, there have been numerous development milestones and significant growth as we have welcomed a number of highly-regarded referral centres and exceptional first opinion brands to the Linnaeus family. Lynne leaves us with a great legacy and a very bright future."
Linnaeus is due to make an announcement on Mrs Hill’s successor shortly.
The programme offers a structured and heavily supported first year in practice, including hands-on surgical training and seminars from Advanced Veterinary Practitioners, at the Pets'n'Vets' Roundhouse Veterinary Hospital in Glasgow.
Totally Grad! also includes a mentor plan and additional monthly benchmarking and seminars and support.
Oliver Jackson, partner at Pets'n'Vets said: "We are well aware that many larger veterinary entities run new graduate programmes and we are proud to say that Totally Grad! offers great advantages that come with our independent structure.
"Independent practice can offer a rewarding working environment for new graduates – particularly progressive practices such as ours. We can offer new graduates not only the close-knit, friendly, helpful, stable, first-opinion experience, but also provide opportunities for career growth and development.
"We have the facility for graduates to explore their particular areas of interest. Indeed, in our practice it is possible for a new graduate to change our way of working – the decision-makers are available and listening. We now have many vets working with us who have come through the practice from our graduate system and who have gone on to help shape our practice.
"The success of our Laparoscopic and Cardiology clinics can be attributed to those vets, as can various other client service initiatives and ways of working. New blood brings new ideas and we welcome that."
Totally Grad! will also be open to fellow independent practices.
Oliver added: "By opening up our Totally Grad! programme, we are offering a simple, accessible facility to those fellow independent practices able and willing to provide a mentor and allow their graduate vets to be out of their practice for one or two days per month over a 12 month period. It fits perfectly with our Roundhouse Referrals offering which offers advice, CPD and support to local practices."
Any independent practices interested in participating in the programme can contact oliver.jackson@petsnvets.org while final year students interested in learning more about the programme can visit the website at www.totallygrad.co.uk and/or email Karen W at hello@totallygrad.co.uk
Researchers say that whilst widely discussed, many in the profession may not be aware that prevalence of the disease has been steadily increasing across all regions of the UK.
Since November 2012, 177 cases have been reported, with more than 90% between November and May. However, the cause of CRGV, which often presents as ulcerations to the dog’s skin and can lead to acute kidney injury (AKI) and potentially death, remains unknown.
Practices are being now asked to report suspect cases in a bid to gain vital insight into the disease and what may be causing it.
David Walker BVetMed (Hons) DipACVIM DipECVIM-CA from Anderson Moores (pictured right) is helping lead the research: "CRGV is a disease that impacts lots of breeds across the UK. Reports show there is seasonality to the disease and therefore an environmental cause is a possible component in its development.
"This research is part of the puzzle and will hopefully help to guide further work on this disease. By collecting more information on confirmed cases, such as walking habits and diet, we hope to build more understanding in order to better protect pets and inform treatment decisions."
To gather this information, Anderson Moores is asking practices to share a 10-minute online survey with the owners of dogs in which CRGV has been confirmed, as well as some control dogs following criteria provided with the survey link.
David said: "Many pet owners are aware of this disease and are concerned for their pets; if they are asked to help they are usually happy to do so. By offering a direct link to the survey, very little of the veterinarian’s time is needed to collate the information."
If you have a suspected case of CRGV, contact Anderson Moores on 01962 767920 or email medicine@andersonmoores.com
If the pet does not survive, then histopathologic assessment of tissue will be performed free of charge to confirm the diagnosis.
In confirmed cases the veterinary surgeon will be sent a link to a 10-minute survey to be completed by the owner.
Along with encouraging the owner of the confirmed case to take part, four unaffected control cases from the same clinic, on the same day, will also need to be recruited.
When a set of five qualifying surveys (one confirmed case and 4 control cases) are provided, practices can claim an Amazon Echo Dot, provided by Bayer, as a thank you for helping with the research.
According to the charity, FIP, which is one of a number of chronic viral infections of cats that resemble those in people, is estimated to kill up to 1.4% of cats around the world.
The infectious agent is a mutant coronavirus (FIPV) that is notoriously difficult to control: the parent enteric coronavirus is present in virtually all catteries and shelters and is shed by 60% or more of pet cats from multi-cat households,1 and vaccines are ineffective.
Among the most promising treatments against emerging viruses in humans is 'GS-5734', one of the small-molecule antivirals targeting specific proteins involved in RNA virus replication.
In studies, it has proven effective in preventing Ebola in rhesus monkeys and inhibiting coronaviruses both in tissue culture and in mouse infection models.
It was these findings that brought it to the attention of a team of veterinary researchers in the USA, led by Professor Niels Pedersen of the University of California, Davis.
Their own initial studies involving experimental FIP showed that the less chemically complex 'GS-441524', the parent nucleoside of GS-5734, was highly effective, opening the way for a field trial in cats with naturally occurring FIP, the results of which are published in this week's JFMS2.
Thirty-one cats, ranging in age from 3–73 months, were enrolled in the study, and 26 completed the planned 12 weeks or more of treatment; the remainder died or were euthanised due to their severe disease.
For these 26 cats, the clinical response was dramatic: fever usually resolved within 12–36 h, concurrent with a marked improvement in appetite, activity levels and weight gain.
In cats with the more common effusive or ‘wet’ form of FIP, abdominal effusions rapidly disappeared, starting at around 10–14 days after commencing treatment.
Encouragingly, and somewhat unexpectedly, cats with non-effusive (‘dry’) FIP and older cats responded as well to GS-441524 treatment as did cats with effusive FIP and young cats. The safety profile of GS-441524 was likewise impressive.
Currently, 24 of the 26 cats remain healthy, with one having succumbed to FIP disease and one to unrelated heart disease. Eighteen of these cats underwent just one round of treatment; the remaining eight suffered disease relapses, but these were successfully treated with a further (in two cases, a third) round of treatment at a higher dose.
Previously the prospects for cats with FIP were bleak. In a review paper on FIP published in JFMS a decade ago, Professor Pedersen stated: "no treatment has proven effective in curing cats of FIP, in spite of the claims. Cats that develop FIP inevitably die of their disease in days, weeks or months."1
Now, as he approaches the end of his professional career, Professor Pedersen is considerably more optimistic: "FIP has been my fascination for the past 50 years and I am fortunate to have reached a final stage in my career having identified safe and effective antiviral drugs. We now know that small molecules targeting specific steps in RNA virus replication are capable of safely curing various forms of FIP."
However, he cautioned: "It must be emphasised that the field trial we report was for proof-of-concept and the results cannot be immediately translated into commercially available products.
"Unfortunately, the real hope provided by these initial trials has increased, and not decreased, the desperation of owners to seek out these new drugs on the black market. As eventful as these discoveries may be, there is still much more about FIP to discover.
"I would like to thank all of the people, organizations and owners who have assisted in my research over this half century and leave remaining questions and associated discoveries for my fellow FIP researchers."
Photo: Bubba, one of the study cats, in recovery. Courtesy Adel Gastle
According to the authors, Miniature Schnauzers positively shone in their averageness in this study, because they were not commonly affected by any specific breed-related health problems.
In other words, the illnesses suffered by Miniature Schnauzers are just the common or garden things like dental disease, obesity, anal sac impaction, vomiting and ear infection, which can affect all dogs.
The study, which the authors say was the largest ever study of the breed, analysed 3,857 Miniature Schnauzers from a population of over 450,000 dogs across the UK. Its findings were that:
The average lifespan of Miniature Schnauzers was 11.7 years, which is similar to the average of 12.0 years for dogs overall.
The average adult bodyweight of Miniature Schnauzers was 10kg. Males on average were heavier than female breeds (11kg vs 9kg).
The most common disorder affecting the breed was dental disease (affecting 17.4% Miniature Schnauzers). This is similar to that of other similarly-sized breeds such as the Cavalier King Charles Spaniel (15.2%) and Border Terrier (17.6%).
Female Miniature Schnauzers are more likely to have dental disease, obesity/overweight and heart murmur. However, males are more prone to diarrhoea and claw injury.
The most common causes of death were neoplasia (14.7%), collapse (13.3%), mass-associated disorder (10.7%) and brain disorder (10.7%).
Dr Dan O’Neill, Senior Lecturer in Companion Animal Epidemiology at the RVC and Vet Compass researcher, said: "To do their best for their dogs, owners need to know what aspects of their dog’s health are the most important to protect. Thankfully, we now have the data to identify these: owners of Miniature Schnauzers and also dogs overall should pay special attention to dental care, weight management, anal sac issues and making sure their dogs eat a healthy diet."
"Based on VetCompass Programme data, the Miniature Schnauzer is currently Britain’s most average dog from the breeds that we have studied to date. Extreme breeds such as flat-faced, long-backed or teacup-sized dogs may currently be in vogue but we need to move away from extremes and towards the healthier middle-ground."
Dr Alex Gough of Independent Vet Care and co-author added: "Although a number of diseases were identified in the current study that affect Miniature Schnauzers, the commons ones did not occur more frequently in this breed than in others studied. Many popular breeds are prone to life-threatening and distressing conditions related to their breeding. Our study suggests that the Miniature Schnauzer should be considered as a relatively healthy breed, which can help owners make a decision when acquiring a new dog."
Bill Lambert, Senior Health and Welfare Manager at the Kennel Club, said: "The Kennel Club currently recognises 221 different breeds and registering these breeds with the Kennel Club provides opportunities for data to be collected so that it can contribute to high quality and large scale research, such as this study by the Royal Veterinary College.
'It is vitally important that this type of research is carried out so that breed specific information is gathered and can be made available to owners to help ensure their dogs are kept as fit and healthy as possible.
'The Miniature Schnauzer is a popular breed in the UK so being the ‘most average dog’ in terms of health, and having no breed specific health problems, is actually a good quality and is very welcome news.”
According to the company, stock is now at normal levels in all the major wholesalers. Laura Jenkins, Companion Animal Marketing Manager at the company added: "IsoFlo is now with veterinary customers and we have a full schedule of deliveries for 2019.
"With restocking underway and ample stock awaiting dispatch, plus enough to re-establish safety stock levels shortly, it is good to know practices will be returning to IsoFlo.
"As our teams work to get IsoFlo to you if you have any questions please do get in touch with your local Account Managers.
"We appreciate other suppliers might be sharing information on their stock and we want to reassure our customers of the immediate availability of IsoFlo and once again I would like to extend thanks to the extended team of associations, veterinary surgeons and regulatory bodies who have helped to find other solutions over the two months."
The practice makes ecobricks by packing all sorts of plastic waste tightly into plastic bottles which can then be joined together using tyres, silicone, cob or cement and used for a wide range of purposes in gardens, play parks and for making all types of structures with.
The ecobrick initiative was launched by the Global Ecobrick Alliance, which describes itself as an Earth Enterprise focused on solving plastic pollution through the dissemination of the low-tech, educational, open source ecobrick technology. It also operates a website which lists a wide range of organisations throughout the world where newly-made ecobricks can be delivered to.
White Cross Vets operates 19 practices, with four in the local area in Gateacre, West Derby, St Helens and Widnes, and is now exploring how it can roll out the scheme across the group. Other green initiatives White Cross Vets is pioneering include rolling out energy efficient LED lighting across its practices and heavily promoting the Cycle to Work scheme.
Helen Morris, from White Cross Vets, said: "In our industry almost everything comes packed in unrecyclable plastics, from small syringe packets through to large delivery bags and the plastic on the backs of patient labels, which we print hundreds of every day.
"As a result, we decided to look at how we might be able to put it to good use, rather than simply putting it in the bin and came across ecobricks. By taking the time to fill the bottles with plastic, we can significantly reduce the waste we send to landfill, and cut the amount of plastic that ends up littering the planet and ultimately finds its way into the sea. We are now making them every week and the whole team gets involved, which is rewarding for everyone involved."
The clinic is led by Sebastien Behr MRCVS, an RCVS Specialist in Neurology. Patients will benefit from access to the referral centre's MRI scanner and its specialist imaging, anaesthesia and neurology teams.
Dr Behr said: "We are very excited to have launched this specialist clinic. Following detailed consultations with pet owners, the animals will be treated to the very highest level and bespoke care designed for each patient."
The practice is offering a fixed price package for routine diagnostic procedures.
For more information, visit www.willows.uk.net or contact the neurology team on 0121 721 7070.
In a statement, the company explained that elevated vitamin D can cause vomiting, loss of appetite, increased thirst, increased urination, excessive drooling, and weight loss. At high levels, it can lead to serious health issues in dogs including renal dysfunction.
The company is inviting 'pet parents' (dear god, spare me) whose dogs are suffering symptoms after eating the products to contact their veterinary surgeon.
Hill's also says it will cover the cost of testing total calcium, albumin and 25OH-Vitamin D3 metabolites in animals which have consumed affected products, at the VitDAL Lab at the Edinburgh Veterinary School.
The affected products are:
The show follows veterinary surgeons and nurses going about their day-to-day work, consulting and operating on a variety of cases from the routine to the extraordinary.
The ten-episode series stars Cat Henstridge, who many will be familiar with for her social media posts as 'Cat the Vet', and her husband Dave Hough who is the Clinic Director at the practice.
Cat said: "I know from the reactions I get on my website and social media channels that there is a huge level of interest in what we do, and the TV programme will help to bring those real-life stories directly to a younger audience, as well as offering exclusive behind the scenes access to everything that happens in our busy veterinary practice."
Dave added: "We are thrilled to be showcasing the fantastic work of our dedicated and talented team. What we see every day is so varied, and we are driven by our love of pets and the ability to help heal them. It’s a real delight to think that our work will be seen on television, and hopefully inspire the next generation of vets, nurses and support staff to work in this really rewarding profession."
It is believed to be the first time the Royal Society of Medicine Pain Section Council, which comprises medical practitioners and consultants, has appointed a veterinary surgeon as President.
The Royal Society of Medicine is one of the country's major providers of postgraduate medical education and presents a neutral platform for informed debate about important, often controversial, healthcare topics.
The RSM has 56 Sections, encompassing all medical specialties. Membership of the RSM is diverse and whilst primarily catering for the needs of Medical Doctors its membership includes nurses, dentists, veterinary surgeons and other health professionals such as physiotherapists.
Louise took over the two-year Presidency on 1st October. Her immediate predecessor was Dr Anthony Ordman, Consultant in Pain Medicine and founder of the Pain Medicine Clinic at the Royal Free Hospital, London.
Louise said: "I am delighted to have the honour of serving as Section President and together as a Section Council we hope to build the profile of the RSM as a source of education for veterinary as well as medical specialists."
Surrey-based Sarah Taylor and Zoe Daley launched the website earlier this year with a range which includes the Medicat wrap to make it easier to medicate and examine cats, and the Slumberpet Recovery Coat for dogs and for cats, for maintaining temperature during anaesthetics.
In addition, they've got a range of funky scrub caps, plus ID tags for your scissors and stethoscopes, fob watches, scrub hats and pens.